SS-31 Peptide Research for Ulcerative Colitis
New research suggests the SS-31 peptide may help treat ulcerative colitis by restoring mitochondrial function and reprogramming immune cells. Learn what the study found.
A growing body of evidence suggests that mitochondrial dysfunction sits at the heart of chronic inflammatory bowel conditions — and a newly published study may offer one of the most targeted therapeutic strategies yet. Research published in the Journal of Gastroenterology and Hepatology (Mei et al., 2026) describes a sophisticated nanoparticle platform built around the SS-31 peptide that demonstrated meaningful reductions in colitis severity in preclinical models, pointing toward a potentially translational approach for the millions of patients living with ulcerative colitis (UC).
What This Study Found
Researchers designed a multi-layered nanoparticle system — designated KSF@SS31@S100Ns — that combined three key components: kaempferol (a plant-derived flavonoid) loaded into silk fibroin nanoparticles, the mitochondria-targeting peptide SS-31, and a pH-sensitive polymer coating (Eudragit S100) intended to protect the formulation from degradation in the stomach and release its payload specifically in the colon.
The nanoparticles measured approximately 307 nanometers in diameter, demonstrated high physicochemical stability, and exhibited the pH-dependent drug release behavior the researchers intended. The inclusion of SS-31 — a synthetic tetrapeptide known for its ability to localize to the inner mitochondrial membrane — significantly enhanced uptake by macrophages and improved delivery directly to mitochondria within those cells.
In laboratory experiments using LPS-stimulated RAW264.7 macrophage cells, the researchers found that KSF@SS31Ns:
- Restored mitochondrial membrane potential and ATP production
- Reduced reactive oxygen species (ROS) accumulation
- Promoted mitophagy — the cellular process of clearing damaged mitochondria
- Activated the SIRT3/FOXO3a signaling pathway, a key regulatory axis governing mitochondrial homeostasis and oxidative stress defense
- Shifted macrophages from a pro-inflammatory M1 phenotype toward an anti-inflammatory M2 phenotype
In a dextran sulfate sodium (DSS)-induced mouse model of colitis, oral administration of the full nanoparticle system — including the S100 coating — resulted in preferential accumulation of the particles within inflamed colonic tissue. The study found that treated mice experienced reduced disease severity, lower levels of pro-inflammatory cytokines, elevated interleukin-10 (an anti-inflammatory marker), restoration of tight-junction proteins critical to gut barrier integrity, and a measurable increase in M2-polarized macrophages within colonic tissue.
It is important to note that these findings were generated in cell culture and animal models. Human clinical trials have not yet been conducted, and replication in human subjects will be necessary before any conclusions about clinical efficacy can be drawn.
Clinical Significance
Ulcerative colitis affects an estimated 5 million people globally and is characterized by chronic, relapsing inflammation of the colon. Current treatment options — including aminosalicylates, corticosteroids, immunosuppressants, and biologics — offer meaningful but incomplete disease control for many patients, and long-term use carries significant side effect burdens.
What makes this research mechanistically notable is its focus on macrophage reprogramming via mitochondrial restoration. The study's authors propose that mitochondrial dysfunction in macrophages is not merely a downstream consequence of intestinal inflammation but may actively drive the pro-inflammatory M1 polarization that perpetuates UC. By targeting this upstream dysfunction with SS-31, the nanoplatform attempts to correct the immunological imbalance at its metabolic source rather than simply suppressing cytokine output.
The SIRT3/FOXO3a pathway activated in this study has attracted considerable scientific interest in inflammation and aging research. SIRT3 is a mitochondrial deacetylase that regulates oxidative stress responses, and its downstream target FOXO3a governs antioxidant gene expression. The study suggests that restoring this signaling axis through mitochondria-targeted peptide delivery may offer a novel lever for shifting macrophage behavior in inflammatory disease.
The colon-targeted oral delivery system also addresses a practical challenge in IBD therapeutics: getting therapeutic agents to the site of inflammation without systemic exposure that can cause off-target effects. The pH-sensitive S100 coating, which remained intact in the acidic environment of the stomach and dissolved in the neutral-to-alkaline environment of the colon, represents a clinically relevant delivery strategy that researchers suggest could support translation to human use.
Current Access and Compliance Context
The KSF@SS31@S100Ns nanoparticle system described in this study is a preclinical investigational formulation and is not currently approved or available as a therapeutic product. SS-31 (also known as elamipretide or Bendavia) is a research peptide that has been studied in various contexts involving mitochondrial dysfunction, including heart failure and renal ischemia-reperfusion injury, but it has not received regulatory approval for any indication as of the time of this publication.
Researchers and clinicians interested in the broader landscape of SS-31 and mitochondria-targeted peptide research should consult peer-reviewed literature and work within the framework of appropriately supervised clinical or research settings. Peptide-based investigational compounds require careful formulation, dosing characterization, and safety evaluation before human application.
Patients currently managing ulcerative colitis should continue working with their gastroenterologists to optimize existing evidence-based treatment regimens while remaining engaged with emerging research developments.
What Patients Should Know
If you or someone you care for is living with ulcerative colitis, the following context may help frame this research appropriately:
This is early-stage research. The experiments were conducted in cell cultures and mice. While the results are scientifically compelling and the mechanistic rationale is well-supported, animal studies frequently do not translate directly to human outcomes. Human clinical trials would be required to confirm safety and efficacy.
The science points to mitochondria as a meaningful target. The concept that immune cell metabolism — specifically mitochondrial health in macrophages — influences the inflammatory environment of the gut is an active and growing area of investigation. This study adds to a body of evidence suggesting that restoring cellular energy metabolism may be as important as directly suppressing immune signaling.
Peptide research is advancing rapidly. SS-31 and related mitochondria-targeting peptides are subjects of ongoing investigation across multiple disease areas. Staying informed about developments in this field — through reputable sources and qualified healthcare providers — is a proactive step for patients interested in emerging options.
Do not attempt to self-administer research peptides. Unregulated access to investigational compounds outside of supervised medical or clinical research contexts carries significant and unpredictable risks. Any interest in peptide-based therapies should be discussed with a knowledgeable and licensed healthcare provider.
Conclusion
The study by Mei and colleagues represents a carefully engineered, mechanistically coherent approach to one of the most persistent challenges in inflammatory bowel disease treatment. By combining the mitochondria-targeting properties of the SS-31 peptide with colon-specific oral delivery technology, the researchers suggest it may be possible to correct the immunological dysfunction driving ulcerative colitis at its metabolic root — without the systemic side effects that limit many current therapies.
While human data are still needed, the preclinical evidence outlined in this study offers a scientifically grounded basis for continued investigation into peptide-based, mitochondria-targeted strategies for inflammatory bowel disease.
If you are interested in learning more about how emerging peptide research may be relevant to your health, we encourage you to connect with a qualified provider through the Peptide Association's physician directory. Find a knowledgeable doctor near you at peptideassociation.org/find-a-doctor.
Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The research described herein involves preclinical models; findings have not been validated in human clinical trials. Always consult a qualified and licensed healthcare provider before making any decisions related to your health or treatment. The Peptide Association does not endorse any specific therapeutic product or investigational compound.
Citation (AMA Format): Mei R, Zhang R, Li Z, et al. Oral colon- and mitochondria-targeted nanoparticles alleviate ulcerative colitis by reeducating macrophage polarization via SIRT3/FOXO3a-mediated mitochondrial restoration. J Gastroenterol Hepatol. 2026. doi:10.1111/jgh.70668. PMID: 42638278.
Ready to work with a peptide-specialized clinician?
The Peptide Association works with licensed clinicians across the United States who specialize in peptide therapy, with telehealth options available in most states.
Disclosure: Peptide Association LLC has a financial relationship with this provider and receives compensation when you book or become a patient. This is a paid referral. See exactly how we make money.